Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
Net sales by source of income are mainly distributed between products sales (78.3%) and sale of collaboration services (19.3%; especially research and development services).
More about the company